TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39187877
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT)
Study: 38824918
Drug: Hydroxyurea treatment
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea treatment
Study: 33264302
Drug: Concurrent challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent challenge naïve subjects with B7A strain at 109 cfu
Study: 33752794
Drug: FENIX (magnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: FENIX (magnetic sphincter augmentation device)
Study: 34765482
Drug: MTEI-(I) at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTEI-(I) at 1 mL/kg/d (Group A)
Study: 34765482
Drug: MTEI-(I) at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTEI-(I) at 2 mL/kg/d (Group B)
Study: 32896089
Drug: Systematic education,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic education, patient diary to mark daily medicine intake, and periodic telephone reminders
Study: 32506663
Drug: MAPC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAPC treatment
Study: 35595003
Drug: Pretomanid (doses:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretomanid (doses: 50, 100, 200, 400, 600, 800, 1000 mg)
Study: 32702837
Drug: Sihogayonggolmoryeo-tang (SYM)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sihogayonggolmoryeo-tang (SYM) granules administered twice a day for 4 weeks
Study: 35688623
Drug: Ultra-low-dose chest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose chest CT (ULDCT)
Study: 35963802
Drug: Olpasiran (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olpasiran (all doses)
Study: 34518264
Drug: guselkumab maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: guselkumab maintenance dosing every 8 weeks (q8w)
Study: 34518264
Drug: guselkumab investigational
Approvals — FDA: no, EMA: no, PMDA: no
Description: guselkumab investigational maintenance dosing every 16 weeks (q16w)
Study: 616830555
Drug: Tomato juice
Normalized name: TOMATO JUICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato juice (30 mg of lycopene) consumed daily for 12 weeks
Study: 616830555
Drug: Antioxidant capsule
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant capsule (vitamin C 600 mg, vitamin E 200 mg, glutathione 300 mg) consumed daily for 12 weeks
Study: 32462935
Drug: Improvement strategies
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Improvement strategies designed to boost academic success and persistence during the 6-month learning and development (L&D) phase of the program.
Study: 34956218
Drug: Oats (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oats (80 g daily for 45 days)
Study: 34956218
Drug: Rice (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice (80 g daily for 45 days)
Study: 33556319
Drug: Peginterferon lambda
Normalized name: Peginterferon lambda-1a
DrugBank: Peginterferon lambda-1a (DB14767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon lambda 180 µg
Study: 32916132
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg (2 capsules of 4 mg) administered orally 1 hour before dental extraction
Study: 32916132
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 capsules with same characteristics as dexamethasone) administered orally 1 hour before dental extraction
Study: 33724251
Drug: Dasotraline 6
Normalized name: Dasotraline
DrugBank: Dasotraline (DB12305)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasotraline 6 mg/day
Study: 32980184
Drug: Placebo (inactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (inactive control vehicle, infused over 30 min, once daily for 7 days)
Study: 35429465
Drug: 12-month oral
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month oral itraconazole
Study: 34699671
Drug: Topical tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tranexamic acid after dermapen microneedling
Study: 34529341
Drug: Topical minoxidil
Normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical minoxidil 2% solution
Study: 34787858
Drug: Routine intravenous
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine intravenous injection
Study: 33012017
Drug: Photobiomodulation and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation and topical clobetasol 0.05%
Study: 34103345
Drug: Avoiding antiplatelet
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avoiding antiplatelet therapy
Study: 37811523
Drug: Tadalafil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (20 mg)
Study: 33248743
Drug: Training clinicians
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Training clinicians to increase TUD treatment
Study: 34253180
Drug: Medication usage
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication usage
Study: 35457632
Drug: Moderate-intensity physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-intensity physical activity program (twice a week for 8 weeks)
Study: 32421444
Drug: Standard anthracycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anthracycline plus ifosfamide neoadjuvant chemotherapy (A+I)
Study: 33950073
Drug: Motivational interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviewing associated with cognitive behavioral therapy (CBT)
Study: 34302893
Drug: High-sensitivity cardiac
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sensitivity cardiac troponin T (hs-cTnT) levels before treatment
Study: 33587659
Drug: Higher-dose edoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose edoxaban regimen
Study: 32873667
Drug: Pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30 mg per day
Study: 32250066
Drug: 1-day preparation
Normalized name: Caviar Preparation
DrugBank: Caviar, unspecified (DB14241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-day preparation using PEG 3350 (4 g/kg/day) + bisacodyl
Study: 35554590
Drug: Suvorexant (initially
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suvorexant (initially 10 mg, increased to 20 mg after 1 week if tolerated)
Study: 32223585
Drug: Fascial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fascial therapy (three 45‐min sessions over a 3‐week period)
Study: 33276518
Drug: Oral resveratrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral resveratrol supplementation for 4 days
Study: 33276518
Drug: Oral resveratrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral resveratrol supplementation
Study: 33475318
Drug: Combination model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination model
Study: 34285713
Drug: COC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: COC with GR blockade (mifepristone; 80.0 mg/kg; po)
Study: 34285713
Drug: COC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: COC with MR blockade (spironolactone; 0.25 mg/kg; po)
Study: 34285713
Drug: COC (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: COC (1.0 μg ethinylestradiol and 5.0 μg levonorgestrel; po)
Study: 35101832
Drug: Placebo (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (standard treatment)
Study: 33025883
Drug: Caffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated coffee (CC) in non-hyperuricaemic participants
Study: 36251165
Drug: Rencofilstat (RCF)
Normalized name: Rencofilstat
DrugBank: Rencofilstat (DB18246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rencofilstat (RCF) 225-mg soft gelatin capsules with high-fat meal
Study: 32415365
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (IV‐TXA)
Study: 34022863
Drug: Non-opioid postoperative
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-opioid postoperative protocol (standardized non-opioid analgesic prescription, limited rescue opioid prescription, patient education infographic)
Study: 34022863
Drug: Current standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current standard of care (treating surgeons’ pre-trial postoperative analgesic regimen)
Study: 32808504
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy followed by interval debulking surgery (NACT‐IDS) with 3 cycles of NACT and subsequently 3 cycles of adjuvant chemotherapy
Study: 32991207
Drug: Aquatic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquatic Therapy Group (ATG)
Study: 34049943
Drug: Tezepelumab (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezepelumab (700 mg intravenously at 4-week intervals for 12 weeks)
Study: 33075844
Drug: 81-mg daily
Normalized name: glecaprevir
DrugBank: Glecaprevir (DB13879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 81-mg daily aspirin
Study: 34336070
Drug: Conventional rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional rehabilitation treatment
Study: 32710457
Drug: Genotype-guided warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-guided warfarin anticoagulation
Study: 38413986
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (500 mg/day)
Study: 34275457
Drug: Multicomponent intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent intervention including systematic medication review
Study: 35445719
Drug: sarilumab 150
Normalized name: SARILUMAB 150MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: sarilumab 150 mg
Study: 37471590
Drug: sarilumab 200
Normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: sarilumab 200 mg
Study: 36426355
Drug: Probiotics (Bifidobacterium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (Bifidobacterium Tetragenous viable Bacteria Tablets)
Study: 35985981
Drug: Androgen Deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen Deprivation Therapy with Docetaxel
Study: 35985981
Drug: Androgen Deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen Deprivation Therapy without Docetaxel
Study: 32424568
Drug: Monitor group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monitor group (MG)
Study: 33759678
Drug: Supplement (SUPP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement (SUPP) - 200-mL carton of juice-based emulsion containing 3000 mg LC n-3 PUFA (1500 mg DHA and 1500 mg EPA), 8 g whey protein isolate, 400 IU vitamin D3, 150 mg resveratrol
Study: 33759678
Drug: Supplement (SUPP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement (SUPP)
Study: 32122216
Drug: Prasugrel 10
Normalized name: prasugrel 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 10 mg once a day
Study: 37981893
Drug: Low-dose computed
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose computed tomography (LDCT) screening
Study: 32993653
Drug: Echium amoenum
Normalized name: Echium plantagineum seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echium amoenum (EA) 450 mg capsules per day (three times a day) for two consecutive cycles
Study: 33028427
Drug: Flaxseed (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed (20 g/d)
Study: 33028427
Drug: Puffed wheat
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Puffed wheat (25 g/d)
Study: 32773268
Drug: Intravenous steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous steroids only
Study: 32773268
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and periarticular steroids (IVPAS)
Study: 39311825
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion
Study: 33121471
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus Metformin (100 mg aspirin and 250 mg metformin for 8 weeks)
Study: 33121471
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus Placebo (100 mg aspirin and placebo for 8 weeks)
Study: 36372695
Drug: Probiotic (Lactobacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic (Lactobacillus ruteri, 100 mg)
Study: 37824257
Drug: Motivational enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational enhancement therapy (MET)
Study: 33947668
Drug: Home medicines
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home medicines review (HMR) and home-based pulmonary rehabilitation (HomeBase) for COPD patients
Study: 33499659
Drug: TF-CBT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TF-CBT with adjunctive AAT (TF-CBT+AAT)
Study: 33478749
Drug: Rapid induction
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid induction (RI) with TCI of propofol effect‐site (CeCALC) 5.4μg/mL (modified Marsh model)
Study: 33478749
Drug: Slow induction
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow induction (SI) with propofol infusion of 10mg/kg/hour
Study: 33206752
Drug: Colonoscopy after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colonoscopy after 3 hours of colon preparation with 10% mannitol
Study: 33206752
Drug: Colonoscopy after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colonoscopy after 6 hours of colon preparation with 10% mannitol
Study: 33206752
Drug: Colonoscopy after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colonoscopy after 3 hours of colon preparation with 10% mannitol in patients with diabetes mellitus
Study: 37492067
Drug: Naltrexone (opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (opioid antagonist)
Study: 35580976
Drug: Anifrolumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anifrolumab (300 mg every 4 weeks for 48 weeks)
Study: 32764887
Drug: BD-TAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: BD-TAP block with 3 mg/kg of ropivacaine diluted to 60 mL
Study: 34568362
Drug: Esketamine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine (0.1 mg/kg bolus after anesthesia induction, 0.1 mg/kg/h during operation, 0.015 mg/kg/h in PCIA after surgery)
Study: 33380574
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural injections with 1% lidocaine hydrochloride mixed with triamcinolone
Study: 34134591
Drug: Placebo (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (300 mg of corn-starch)
Study: 32231364
Drug: Integrative Adapt
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative Adapt Therapy (IAT)
Study: 33932990
Drug: Theophylline infusion
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline infusion (Group T)
Study: 33932990
Drug: GLP-1 +
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 + Theophylline infusion (Group GT)
Study: 33222710
Drug: Treatment phase
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment phase without hospitalisation
Study: 33222710
Drug: Treatment phase
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment phase without fever
Study: 33222710
Drug: Treatment phase
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment phase with ≤ 2 episodes of diarrhoea
Study: 32488885
Drug: Trazodone 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone 20 mg
Study: 32488885
Drug: Trazodone 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone 60 mg
Study: 32488885
Drug: Trazodone 140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone 140 mg
Study: 34444703
Drug: β-alanine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-alanine (20 g per day for 7 days)
Study: 38102535
Drug: eptinezumab 100
Normalized name: EPTINEZUMAB 100 mg in 1 mL INTRAVENOUS INJECTION [Vyepti]
Approvals — FDA: no, EMA: no, PMDA: no
Description: eptinezumab 100 mg
Study: 34088322
Drug: L-tyrosine-adsorbed allergen
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tyrosine-adsorbed allergen extracts
Study: 39222277
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg once daily)
Study: 35316372
Drug: 6-week supervised
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6-week supervised concurrent chair-based exercise program (stretching, strength, balance exercises, aerobic dance; 5 days/week, 30-40 min/day, 2 workouts/day lasted 15-20 min)
Study: 35770308
Drug: Patient satisfaction
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient satisfaction levels after treatment in Area A (Fractional Er: YAG)
Study: 32623977
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure-lowering therapy (target systolic BP, 110-139 mm Hg)
Study: 32623977
Drug: Standard blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard blood pressure-lowering therapy (target systolic BP, 140-179 mm Hg)
Study: 36260615
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (160 mg daily from inclusion to 34 weeks of gestation)
Study: 36260615
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily from inclusion to 34 weeks of gestation)
Study: 36521773
Drug: Acupuncture intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acupuncture intervention combined with pharmacologic treatment
Study: 35719024
Drug: Family Focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family Focused Therapy (FFT-CHR)
Study: 33648576
Drug: Blended cognitive
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended cognitive behaviour therapy (PowerMe intervention) targeting fatigue, tailored to individual treatment plans, duration of 33 weeks with a baseline period of 5 to 9 weeks before intervention.
Study: 38492517
Drug: Medication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication therapy
Study: 33035763
Drug: Monthly oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly oral health intervention by dental hygienists for 8 months
Study: 33378108
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (electroacupuncture at Hegu point (LI4) and Zusanli point (ST36) and auricular-point pressure on Shenmen point)
Study: 33378108
Drug: Single therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single therapy (only auricular-point pressure)
Study: 34373384
Drug: DKT therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: DKT therapy group
Study: 33459698
Drug: Cupping therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cupping therapy with 45 mm cup
Study: 32221707
Drug: Arm immobilization
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm immobilization without MI treatment
Study: 32310966
Drug: Community-wide mass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-wide mass drug administration (MDA) for STH
Study: 35237860
Drug: Drug-coated balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-coated balloon angioplasty (DCBA)
Study: 34217297
Drug: IVIG administered
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG administered over 12 hours (12H group)
Study: 34217297
Drug: IVIG administered
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG administered over 24 hours (24H group)
Study: 34872087
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia + Circadian Rhythm Support (CBT-I+CRS)
Study: 33939347
Drug: Antihistamine +
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamine + Probiotic (LactoCare)
Study: 33939347
Drug: Antihistamine (Control)
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamine (Control)
Study: 35924398
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral hygiene regimen
Study: 32801436
Drug: EECP Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EECP Therapy
Study: 32801436
Drug: TMZ 35
Normalized name: TMZ
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TMZ 35 mg twice daily + EECP Therapy
Study: 33896356
Drug: Secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 300 mg/2 mL pre-filled syringe
Study: 36917429
Drug: Self-Injection Assessment
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-Injection Assessment Questionnaire (SIAQ)
Study: 39223617
Drug: treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment as usual (TAU)
Study: 34471708
Drug: Positive psychology
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive psychology interventions (PPI) - 10 weekly training sessions